High-quality systematic reviews (SRs) of both new and existing health technologies are vital to inform clinical practices and healthcare decision-making. This has been recognised by global entities such as the World Health Organization and national healthcare policy agencies like the Canadian Agency for Drugs and Technologies in Health, the National Institute for Health and Care Excellence in the United Kingdom, and the National Health and Medical Research Council in Australia. These SRs serve as the foundation for evidence-based practices and policies, which is reflected in the increasing number of publications in recent years.1

SRs comparing more than one intervention are often of interest to knowledge users (e.g., health care professionals and patients).2 This includes, for instance, selecting from a range of medications, such as atypical antipsychotics, haloperidol and dexmedetomidine, for the management of delirium in older patients. When the method of synthesis is quantitative, network meta-analysis (NMA) comparing multiple interventions from a network of trials is commonly used. The increasing use of NMAs reflects the growing need of assessing multiple interventions when evaluating healthcare interventions.3 4 Overall, NMA helps inform clinical decision-making, …